Table 6. Prognostic factors for progression-free survival in patients treated with S-1 plus oxaliplatin with bevacizumab or 5-FU/l-LV plus oxaliplatin with bevacizumab.

	Variables	Base category	SOX/Bev			FOLOX/Bev			All patients
			HR	95% CI	P value	HR	95% CI	P value	HR	95% CI	P value
Sex	Female vs. male	Male	0.90	0.68-1.20	0.49	1.09	0.82-1.44	0.56	0.97	0.79-1.18	0.72
Age	70 ≦ vs. 70 >	70 >	1.05	0.77-1.43	0.77	0.81	0.58-1.12	0.20	0.89	0.71-1.11	0.30
Primary lesion	Rectosigmoid vs. colon	Colon	0.85	0.58-1.24	0.40	0.94	0.63-1.38	0.74	0.89	0.68-1.16	0.40
	Rectum vs. colon	Colon	0.94	0.67-1.30	0.71	0.81	0.59-1.11	0.19	0.85	0.68-1.06	0.15
Histology	Poorly vs. well/ moderate	Well/ moderate	3.33	1.74-6.35	0.0003	1.30	0.63-2.68	0.48	1.89	1.18-3.02	0.0079
	Others vs. well/ moderate	Well/ moderate	1.07	0.66-1.71	0.78	0.87	0.55-1.37	0.55	0.91	0.65-1.25	0.55
Adjuvant chemotherapy	Yes vs. No	No	0.68	0.45-1.02	0.059	0.75	0.51-1.11	0.15	0.75	0.57-0.99	0.038
Target lesion	Yes vs. No	No	0.85	0.51-1.40	0.52	1.17	0.70-1.95	0.58	0.96	0.67-1.37	0.83
Liver metastases	Yes vs. No	No	1.05	0.69-1.59	0.81	0.97	0.62-1.50	0.88	1.03	0.77-1.39	0.82
Lung metastases	Yes vs. No	No	1.19	0.82-1.72	0.35	1.26	0.82-1.94	0.29	1.24	0.94-1.62	0.12
Lymph node metastases	Yes vs. No	No	1.00	0.63-1.58	0.99	0.87	0.58-1.32	0.52	0.98	0.73-1.30	0.87
Other metastases	Yes vs. No	No	0.99	0.64-1.52	0.95	1.02	0.64-1.63	0.92	1.04	0.76-1.42	0.80
Metastatic organs	2 ≦ vs. 1	1	1.08	0.67-1.74	0.74	0.99	0.61-1.60	0.96	1.00	0.72-1.37	0.98
Treatment	SOX/Bev vs. FOLFOX/Bev	FOLFOX/Bev	-	-	-	-	-	-	1.06	0.88-1.28	0.51

FOLFOX/Bev, l-leucovorin, 5-fluorouracil, oxaliplatin, and bevacizumab; HR, hazard ratio; SOX/Bev, S-1, oxaliplatin, and bevacizumab; 95% CI, 95% confidence interval.